Chronic Renal Failure Clinical Trial
— EX-CHRODIALOfficial title:
Chronic Intradialytic Exercise: a Cardioprotective Role
Verified date | November 2023 |
Source | University of Avignon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function.
Status | Completed |
Enrollment | 61 |
Est. completion date | September 30, 2023 |
Est. primary completion date | May 14, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 79 Years |
Eligibility | Inclusion Criteria: - No medical contraindication to physical activity - Life expectancy greater than 6 months - Patients on haemodialysis for more than 3 months Exclusion Criteria: - Pregnancy - Valvular heart disease, - Unstable coronary artery disease - Arteriopathy obliterating of the lower limbs stage III and IV - Musculoskeletal problems - Severe respiratory disease - BMI> 35 - Pacemaker, cardiac stimulation and automatic implantable defibrillator - Heart transplant - Uncontrolled arterial hypertension - Ejection fraction <45% |
Country | Name | City | State |
---|---|---|---|
France | ATIR | Avignon | Vaucluse |
France | Centre Hemodialyse AIDER sante | Nîmes | Gard |
Lead Sponsor | Collaborator |
---|---|
University of Avignon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in myocardial longitudinal deformations | Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. | Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise. | |
Primary | Changes in myocardial longitudinal deformations | Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. | Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise). | |
Primary | Changes in myocardial circumferential deformations | Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. | Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise. | |
Primary | Changes in myocardial circumferential deformations | Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. | Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise). | |
Primary | Changes in left ventricular torsion | Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode. | Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise. | |
Primary | Changes in left ventricular torsion | Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode. | Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise). | |
Secondary | Changes in arterial rigidity | Measurement of pulse wave velocity (m/s) by photo-plethysmography at rest before dialysis. | before (week 0) and after (week 17) an exercise training program of 16 weeks | |
Secondary | Changes in Physical fitness | The six-minute walking test (meters); maximal isometric force (newtons) during a knee-extension test and handgrip test using a dynamometer. | before (week 0) and after (week 17) an exercise training program of 16 weeks | |
Secondary | Health-related Quality of life | The 36-Item Short Form Health Survey questionnaire. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. | before (week 0) and after (week 17) an exercise training program of 16 weeks | |
Secondary | Changes in carotid intimal-media wall thickness | The intimal plus media wall thickness (mm) of the right carotid artery will be measured using high-resolution echography. | before (week 0) and after (week 17) an exercise training program of 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 |